Regulated information

H1 2022 Sales

H1 2022 Sales: €271m, up 6.1%
+2.0% on a like-for-like basis
H1 2022 Essentials Sales: €154m, up 9.8%
+6.8% on a like-for-like basis

Q1 2022 SALES: €135M

Q1 2022 SALES: €135M
(UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES)
Q1 2022 ESSENTIALS SALES: €77M
(UP 8.1% AS REPORTED, UP 5.5 AT CONSTANT EXCHANGE RATES)

First nine months 2022 sales: €405M

In line with year-end outlook

Continued Sales Growth in the second Quarter of 2010

Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth.

Continued sales growth driven by sustained organic growth

April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.

Strong Sales in the 3rd Quarter of 2010

Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments.

2022 HALF YEAR RESULTS

Sales: €271m (up 6.0% as reported)
Essentials sales: €154m (up 9.8% as reported)
EBIT before depreciation of acquired assets: €52m (19.0% of sales)
Net income - Group share: €21m (7.9% of sales)
EBITDA: €62m (22.9% of sales)

Double-digit growth in 2021

Total Group Sales: €521 million (up 21.9% as reported)
Annual Sale of Essential products: €296 million (up 34.0% as reported)

2021 Annual results

ALL FINANCIAL INDICATORS UP.
Annual sales: €521m (up 21.9% as reported).
Essentials sales: €296m (up 34.0% as reported).
EBIT before depreciation of acquired assets: €101m (up 54.5%).
Net income - Group share: €63m (up 226.9%).

Strong growth in 2009 Revenues: +7.6%

January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions.